This company develops antibody-drug conjugates (ADCs) that precisely target and treat autoimmune and inflammatory diseases. Their proprietary ADC platform aims to deliver enhanced efficacy and safety, creating innovative therapies for unmet needs in immunology and inflammation.
Funding
Funding not disclosed
Founders
Product
Problem
Current treatments for autoimmune and inflammatory diseases often lack precise targeting, leading to systemic toxicity and reduced efficacy. This results in significant unmet needs across various medical disciplines, including rheumatology, gastroenterology, pulmonology, and dermatology.
Solution
Lifordi Immunotherapeutics is developing novel therapies for autoimmune and inflammatory disorders using a targeted antibody-drug conjugate (ADC) platform. Their approach leverages the success of ADCs in oncology by directing potent immunosuppressive agents specifically to immune cells, including myeloid and lymphoid cells. The platform targets a cell surface protein, VISTA, which exhibits rapid internalization and intracellular accumulation, making it ideal for ADC-based delivery. Preclinical studies of Lifordi's lead ADC candidate, LFD-200, have demonstrated a short serum half-life and long immune cell residency, resulting in extended immunosuppressive function within these cells without systemic toxicity.
Target Audience
The primary target audience includes patients suffering from autoimmune and inflammatory disorders, as well as pharmaceutical companies seeking innovative and targeted therapeutic approaches in immunology.
Features
- ADC-based delivery platform targeting a cell surface protein (VISTA) expressed on immune cells
- Rapid internalization and intracellular accumulation of the ADC within target cells
- LFD-200, a lead ADC candidate, demonstrates short serum half-life and long immune cell residency
- Ability to exert immunosuppressive function within immune cells for an extended duration
- Reduced systemic toxicity compared to traditional systemic delivery methods
- Applicable to various payloads, including small molecules and nucleic acids
- Potential application across multiple autoimmune and inflammatory conditions in rheumatology, gastroenterology, pulmonology, and dermatology